Published in Opt Express on March 21, 2016
Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys (2007) 6.98
Validation of an accelerated 'demons' algorithm for deformable image registration in radiation therapy. Phys Med Biol (2005) 4.00
Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. Int J Radiat Oncol Biol Phys (2004) 3.21
Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys (2005) 3.19
Estimation of α/β for late rectal toxicity based on RTOG 94-06. Int J Radiat Oncol Biol Phys (2011) 2.96
4D Proton treatment planning strategy for mobile lung tumors. Int J Radiat Oncol Biol Phys (2007) 2.80
Ultrasound-based localization. Semin Radiat Oncol (2005) 2.52
Assessing respiration-induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer. Int J Radiat Oncol Biol Phys (2007) 2.35
Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2008) 2.22
Objective assessment of deformable image registration in radiotherapy: a multi-institution study. Med Phys (2008) 2.15
Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res (2007) 2.13
Image-guided radiation therapy for non-small cell lung cancer. J Thorac Oncol (2008) 1.90
Implementation and validation of a three-dimensional deformable registration algorithm for targeted prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.87
Enhancement of tumor thermal therapy using gold nanoparticle-assisted tumor necrosis factor-alpha delivery. Mol Cancer Ther (2006) 1.86
Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2002) 1.85
Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2006) 1.85
Dosimetry tools and techniques for IMRT. Med Phys (2011) 1.84
Multiple regions-of-interest analysis of setup uncertainties for head-and-neck cancer radiotherapy. Int J Radiat Oncol Biol Phys (2006) 1.75
Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit (2007) 1.73
Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 1.73
Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res (2012) 1.70
Reduce in variation and improve efficiency of target volume delineation by a computer-assisted system using a deformable image registration approach. Int J Radiat Oncol Biol Phys (2007) 1.69
Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One (2012) 1.67
Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol (2011) 1.66
Reducing metal artifacts in cone-beam CT images by preprocessing projection data. Int J Radiat Oncol Biol Phys (2006) 1.65
Effectiveness of noncoplanar IMRT planning using a parallelized multiresolution beam angle optimization method for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys (2005) 1.63
Adaptive radiotherapy for head-and-neck cancer: initial clinical outcomes from a prospective trial. Int J Radiat Oncol Biol Phys (2011) 1.59
DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer. Gastric Cancer (2014) 1.56
Use of deformed intensity distributions for on-line modification of image-guided IMRT to account for interfractional anatomic changes. Int J Radiat Oncol Biol Phys (2005) 1.49
Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.49
Targeted genomic sequencing identifies PRRT2 mutations as a cause of paroxysmal kinesigenic choreoathetosis. J Med Genet (2011) 1.49
Protective effect of a coffee preparation (Nescafe pure) against carbon tetrachloride-induced liver fibrosis in rats. Clin Nutr (2010) 1.48
Performance evaluation of automatic anatomy segmentation algorithm on repeat or four-dimensional computed tomography images using deformable image registration method. Int J Radiat Oncol Biol Phys (2008) 1.47
Novel insulin-like growth factor-methotrexate covalent conjugate inhibits tumor growth in vivo at lower dosage than methotrexate alone. Transl Res (2009) 1.42
Parotid gland dose in intensity-modulated radiotherapy for head and neck cancer: is what you plan what you get? Int J Radiat Oncol Biol Phys (2007) 1.41
Adaptive radiation therapy for head and neck cancer-can an old goal evolve into a new standard? J Oncol (2010) 1.41
Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment. Int J Radiat Oncol Biol Phys (2007) 1.40
Epidemiology of gastroesophageal reflux disease: a general population-based study in Xi'an of Northwest China. World J Gastroenterol (2004) 1.36
Monte Carlo simulations of the dosimetric impact of radiopaque fiducial markers for proton radiotherapy of the prostate. Phys Med Biol (2007) 1.35
Comprehensive analysis of proton range uncertainties related to patient stopping-power-ratio estimation using the stoichiometric calibration. Phys Med Biol (2012) 1.34
Intrafraction prostate motion during IMRT for prostate cancer. Int J Radiat Oncol Biol Phys (2002) 1.33
6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases. Proc Natl Acad Sci U S A (2008) 1.33
A beam-specific planning target volume (PTV) design for proton therapy to account for setup and range uncertainties. Int J Radiat Oncol Biol Phys (2011) 1.31
A catalogue of human saliva proteins identified by free flow electrophoresis-based peptide separation and tandem mass spectrometry. Mol Cell Proteomics (2005) 1.30
An evidence based review of proton beam therapy: the report of ASTRO's emerging technology committee. Radiother Oncol (2012) 1.28
Comparison of 2D radiographic images and 3D cone beam computed tomography for positioning head-and-neck radiotherapy patients. Int J Radiat Oncol Biol Phys (2008) 1.26
Accuracy of two heterogeneity dose calculation algorithms for IMRT in treatment plans designed using an anthropomorphic thorax phantom. Med Phys (2007) 1.26
miR-30 inhibits TGF-β1-induced epithelial-to-mesenchymal transition in hepatocyte by targeting Snail1. Biochem Biophys Res Commun (2011) 1.25
Mechanisms of bone metastases of breast cancer. Endocr Relat Cancer (2009) 1.25
Patterns of disease recurrence following treatment of oropharyngeal cancer with intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys (2012) 1.23
Evaluation of respiratory-induced target motion for esophageal tumors at the gastroesophageal junction. Radiother Oncol (2007) 1.23
Radiobiology of stereotactic body radiation therapy/stereotactic radiosurgery and the linear-quadratic model. Int J Radiat Oncol Biol Phys (2013) 1.22
Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model. Int J Radiat Oncol Biol Phys (2010) 1.21
Automatic registration of the prostate for computed-tomography-guided radiotherapy. Med Phys (2003) 1.21
Comparison of rectal dose-wall histogram versus dose-volume histogram for modeling the incidence of late rectal bleeding after radiotherapy. Int J Radiat Oncol Biol Phys (2004) 1.20
Proteomics analysis of cells in whole saliva from oral cancer patients via value-added three-dimensional peptide fractionation and tandem mass spectrometry. Mol Cell Proteomics (2007) 1.19
Recent advances of laser-spectroscopy-based techniques for applications in breath analysis. J Breath Res (2007) 1.19
Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2007) 1.17
Automatic segmentation of whole breast using atlas approach and deformable image registration. Int J Radiat Oncol Biol Phys (2008) 1.15
A deformable image registration method to handle distended rectums in prostate cancer radiotherapy. Med Phys (2006) 1.14
Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists. J Med Chem (2009) 1.13
Osteoradionecrosis and radiation dose to the mandible in patients with oropharyngeal cancer. Int J Radiat Oncol Biol Phys (2012) 1.13
Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int J Cancer (2005) 1.13
Experience of ultrasound-based daily prostate localization. Int J Radiat Oncol Biol Phys (2003) 1.12
Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys (2011) 1.11
Characterization of microRNA-29 family expression and investigation of their mechanistic roles in gastric cancer. Carcinogenesis (2013) 1.11
Characterization of rectal normal tissue complication probability after high-dose external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2004) 1.11
Simultaneous regeneration of articular cartilage and subchondral bone in vivo using MSCs induced by a spatially controlled gene delivery system in bilayered integrated scaffolds. Biomaterials (2011) 1.11
Involvement of testicular growth factors in fetal Leydig cell aggregation after exposure to phthalate in utero. Proc Natl Acad Sci U S A (2008) 1.09
Dosimetric comparison of four target alignment methods for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys (2006) 1.09
Quality assurance for image-guided radiation therapy utilizing CT-based technologies: a report of the AAPM TG-179. Med Phys (2012) 1.09
MicroRNA-101 suppresses liver fibrosis by targeting the TGFβ signalling pathway. J Pathol (2014) 1.08
Hazards of dose escalation in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys (2003) 1.08
Ultrasensitive detection of nitric oxide at 5.33 microm by using external cavity quantum cascade laser-based Faraday rotation spectroscopy. Proc Natl Acad Sci U S A (2009) 1.08
Adaptive radiotherapy for head and neck cancer--dosimetric results from a prospective clinical trial. Radiother Oncol (2013) 1.05
Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome. World J Gastroenterol (2007) 1.05
An automatic CT-guided adaptive radiation therapy technique by online modification of multileaf collimator leaf positions for prostate cancer. Int J Radiat Oncol Biol Phys (2005) 1.05
Evaluation of mechanical precision and alignment uncertainties for an integrated CT/LINAC system. Med Phys (2003) 1.03
The autoregulatory feedback loop of microRNA-21/programmed cell death protein 4/activation protein-1 (MiR-21/PDCD4/AP-1) as a driving force for hepatic fibrosis development. J Biol Chem (2013) 1.03
Evaluation of a contour-alignment technique for CT-guided prostate radiotherapy: an intra- and interobserver study. Int J Radiat Oncol Biol Phys (2004) 1.03
Nanoparticle preconditioning for enhanced thermal therapies in cancer. Nanomedicine (Lond) (2011) 1.03
Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer. Int J Radiat Oncol Biol Phys (2012) 1.03
Comparison of temperature curve and ablation zone between 915- and 2450-MHz cooled-shaft microwave antenna: results in ex vivo porcine livers. Eur J Radiol (2011) 1.01
Long non-coding RNA LSINCT5 predicts negative prognosis and exhibits oncogenic activity in gastric cancer. Medicine (Baltimore) (2014) 1.01
Chlorogenic acid reduces liver inflammation and fibrosis through inhibition of toll-like receptor 4 signaling pathway. Toxicology (2012) 1.01
Estrogen reduces CCL4- induced liver fibrosis in rats. World J Gastroenterol (2002) 1.00
Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.00
Do intermediate radiation doses contribute to late rectal toxicity? An analysis of data from radiation therapy oncology group protocol 94-06. Int J Radiat Oncol Biol Phys (2012) 1.00
Elastic image mapping for 4-D dose estimation in thoracic radiotherapy. Radiat Prot Dosimetry (2005) 1.00
Tumor-Endothelial Cell Three-dimensional Spheroids: New Aspects to Enhance Radiation and Drug Therapeutics. Transl Oncol (2011) 1.00
Quantification of prostate and seminal vesicle interfraction variation during IMRT. Int J Radiat Oncol Biol Phys (2008) 0.99
QEPAS based ppb-level detection of CO and N2O using a high power CW DFB-QCL. Opt Express (2013) 0.99
Effectiveness of using fewer implanted fiducial markers for prostate target alignment. Int J Radiat Oncol Biol Phys (2009) 0.99
Speed and convergence properties of gradient algorithms for optimization of IMRT. Med Phys (2004) 0.99
Transcriptome analysis of tree peony during chilling requirement fulfillment: assembling, annotation and markers discovering. Gene (2011) 0.99
Chlorogenic acid against carbon tetrachloride-induced liver fibrosis in rats. Eur J Pharmacol (2009) 0.98
Dosimetric accuracy of Kodak EDR2 film for IMRT verifications. Med Phys (2005) 0.98
Proton radiotherapy for liver tumors: dosimetric advantages over photon plans. Med Dosim (2008) 0.98
QEPAS based detection of broadband absorbing molecules using a widely tunable, cw quantum cascade laser at 8.4 mum. Opt Express (2007) 0.98
Photothermal nanodrugs: potential of TNF-gold nanospheres for cancer theranostics. Sci Rep (2013) 0.97